Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. - Wikidata - awgldk - TriplyDB

Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

http://www.wikidata.org/entity/Q34660856

about

Pharmacogenetics and outcome with antipsychotic drugs Genetics of Common Antipsychotic-Induced Adverse Effects Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes Experimental evidence for the involvement of PDLIM5 in mood disorders in hetero knockout mice.Antipsychotic-induced movement disorders in long-stay psychiatric patients and 45 tag SNPs in 7 candidate genes: a prospective study Treatment of neurolept-induced tardive dyskinesia Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis.Possible biomarkers modulating haloperidol efficacy and/or tolerability.Pharmacogenetics of tardive dyskinesia: an updated review of the literature.Common variants on 17q25 and gene-gene interactions conferring risk of schizophrenia in Han Chinese population and regulating gene expressions in human brain.Support for association of HSPG2 with tardive dyskinesia in Caucasian populations.DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia.Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.Possible association between DBH 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia.Investigation of the Gene in Tardive Dyskinesia - New Data and Meta-Analysis

P2860

Q26852807-72342E93-A47F-432D-A40D-FE9DD9DC4F31 Q28072893-F0BD7564-CE88-46FB-986D-1EB8224C26B7 Q28088705-945EB528-9E67-4607-A034-F3F41AA2B5DE Q30455448-7F187D77-5461-498A-84DE-08FA86D69F70 Q34506671-4E555D65-083F-4DE5-A4C2-C089259981B3 Q37198420-ED40E67A-339B-4F57-BCF7-15323AB3F161 Q38032249-BBF68F36-1BD6-4DCB-AECF-C4797848DAFE Q38792346-83FE41EE-AE53-4FA7-82DE-513EC9725D87 Q38911685-69D7E0CF-2F2F-4A6E-9D96-EEC7DC8711E6 Q40147944-5B29E7F6-C22E-4074-9C90-0F533A87CC21 Q44208517-EEC61FB2-4C8D-4DE3-8A99-95410669BACB Q44582314-3B2BA9E7-4560-427E-B735-8EFC41BB65B0 Q45007058-FDC96456-9D9B-4BB9-ACE2-756752C5B513 Q48006592-66FC1B6D-D298-4556-9488-389408F14A9F Q50616840-2B0A51D2-B788-4FE5-93A7-728DBBCEAAF5 Q57073796-F60DF555-1884-4900-B1F7-3C97B56CCAE6

P2860

Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

http://www.wikidata.org/entity/Q34660856

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

@en

Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

@nl

type

label

Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

@en

Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

@nl

prefLabel

Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

@en

Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

@nl

P1433

Q34660856-AFD264AB-C7FE-4F6A-BE90-752E905D83E6

P1476

Q34660856-821651CB-C108-4CE2-9EB9-82D3B1E6D6E3

P2093

Q34660856-02535ABF-833E-4DED-AF29-35EA4EBE7951

Q34660856-12DDF7ED-3D29-459B-804B-EEDC1A6398BD

Q34660856-28D2F52E-6B55-4D7C-A465-434E4538C3CD

Q34660856-3498477B-C704-40EF-BD20-527559C7C464

Q34660856-3561D2DE-8115-46B3-B0EB-76FD76909EDA

Q34660856-3A519F74-DDFE-4AD5-BF6B-4AC180502419

Q34660856-4B16C7CE-44F9-46ED-9CA3-5C9F232FC6CC

Q34660856-5F9660E2-9451-41A8-BB7E-4374F8260657

Q34660856-731585E3-47EA-4FE6-A0ED-19B2B6198560

Q34660856-7FF41223-4CC9-4CA9-B97E-58C4067CE752

P2860

Q34660856-04B84E4E-02CE-4327-BDE6-0DA0D316BA33

Q34660856-04FE49C2-F301-4548-8822-0E108353CD09

Q34660856-05BBABC0-6AB0-4779-AE81-9E19EBF49A72

Q34660856-06ED2B53-ECD0-43D1-B80E-15D8E0413DF9

Q34660856-12FE8437-CB7E-44C0-893F-284359F0EC0B

Q34660856-16529D65-B276-4E32-9E80-C48680739D98

Q34660856-19E73C82-4FC6-438E-AEA6-7F0551E37E53

Q34660856-2DFA2A98-DD44-4C3A-AE39-EC127393C3D5

Q34660856-36B7A75D-EDCE-48E4-BEC1-2A69C087C413

Q34660856-4DC41F26-1213-4032-BC4A-64674D4F52DE

P2888

Q34660856-88B55ED8-D3A0-4199-87B5-18CD050E975D

P304

Q34660856-58F54493-3364-442A-8F18-64A46327FA87

P31

Q34660856-85DA7F7C-44DE-452E-A52B-07612EF16C9F

P356

Q34660856-4D8D2121-92EB-4DF1-90D4-60850382803B

P407

Q34660856-11B95027-829D-45EE-911E-B0EB72007F9A

P433

Q34660856-00089413-20C2-465B-B349-D372B2D84058

P478

Q34660856-C9C34B77-E00D-4860-8AA6-58562BB5FEE4

P50

Q34660856-43E67128-FFA8-4581-A492-C443405B6812

P577

Q34660856-99F5EA13-D528-4B64-911E-B4C113540CC9

P5875

Q34660856-02B85966-CA0C-4B5E-8B3E-70476B87BB9E

P6179

Q34660856-86FB9036-1C30-42B8-A598-2B407F5B1F02

P698

Q34660856-C4FCA97E-2AE5-4398-91F6-8A1FA01D09F6

P921

Q34660856-13AA4ECE-2DA5-421B-BDDB-8AAFC3E1F528

P932

Q34660856-078AAA9A-4813-4D8E-A7CB-DD00AE1FD8B7

P356

P1433

Neuropsychopharmacology

P1476

Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

@en

P2093

Akiyoshi Kakita

http://www.w3.org/2001/XMLSchema#string

Aoi Syu

http://www.w3.org/2001/XMLSchema#string

Eri Arikawa-Hirasawa

http://www.w3.org/2001/XMLSchema#string

Hiroki Ishiguro

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Nawa

http://www.w3.org/2001/XMLSchema#string

Hitoshi Takahashi

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Niizato

http://www.w3.org/2001/XMLSchema#string

Kazuko Keino-Masu

http://www.w3.org/2001/XMLSchema#string

Makoto Arai

http://www.w3.org/2001/XMLSchema#string

Makoto Takahashi

http://www.w3.org/2001/XMLSchema#string

P2860

Perlecan is essential for cartilage and cephalic development

The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases

PRiMA: the membrane anchor of acetylcholinesterase in the brain

Genomic control for association studies

Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.

Cholinergic medication for neuroleptic-induced tardive dyskinesia.

Supportive evidence for reduced expression of GNB1L in schizophrenia.

The current status of tardive dyskinesia.

Pharmacogenetics of psychotropic drug response.

Treatment of tardive dyskinesia with donepezil: a pilot study.

P2888

P304

1155-1164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2009.220

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41013395

http://www.w3.org/2001/XMLSchema#string

P6179

1000992644

http://www.w3.org/2001/XMLSchema#string

P698

20072119

http://www.w3.org/2001/XMLSchema#string

P921

P932

3055411

http://www.w3.org/2001/XMLSchema#string